[Ip-health] KEI Comments on the Draft Concept Note Concerning the WHO General Programme of Work
claire.cassedy at keionline.org
Fri Oct 13 11:05:58 PDT 2017
KEI Comments on the Draft Concept Note Concerning the WHO General Programme
Submitted by Claire Cassedy on 13. October 2017 - 13:55
On October 13, 2017, KEI submitted comments to the WHO regarding the Draft
Concept Note towards the WHO's 13th General Programme of Work. The Draft
Concept Note is available here:
The text of KEI's comments follow below, and a PDF is available here .
Friday, 13 October 2017
Dear Dr. Tedros,
Knowledge Ecology International (KEI) welcomes your election as
Director-General of the World Health Organization (WHO), predicated upon
your vision of achieving universal health care.
In your inaugural address to the staff of WHO on 3 July 2017 you
underscored the point that universal health coverage was the overarching
priority of the organization. In particular, you noted:
“[A]ll roads lead to universal health coverage. For me, the key
question of universal health coverage is an ethical one. Do we want our
fellow citizens to die because they are poor? Universal health coverage, as
I said earlier, is a human rights issue. And the responsibility of national
governments. It’s not only a technical matter but even more so a political
one. Countries should compare their results to their peers and learn from
About 400 million people have no access, as you know, to even basic
health care. Many more have access but will endure financial hardship.
During the coming weeks, we will be looking at how best to implement the
relevant Sustainable Development Goal, achieving universal health coverage,
including financial risk protection, access to quality essential health
care services, and access to safe, effective, quality and affordable
essential medicines and vaccines for all.” (Source: Director-General Dr
Tedros takes the helm of WHO: address to WHO staff,
KEI welcomes the opportunity to submit comments on the Draft concept note
towards WHO’s 13th General Programme of Work 2019–2023 (GPW). The strategic
vision articulated in the draft concept note provides the WHO with a road
map to guide its work from 2019-2023 and “serves as the organizing
framework for two Programme Budgets 2020-2021 and 2022-2023 as well as the
strategic basis for resource mobilization.” (Source: Draft Concept Note
towards WHO’s 13th General Programme of Work 2019–2023,
On Thursday, 12 October 2017, in your address to the WPRO region, you
identified the Organization’s twin priorities - 1) universal health
coverage and 2) health security noting that while the Sustainable
Development Goals (SDGs) give the global health community the “political
mandate to drive significant change...the clock is ticking...We have just
13 years to keep the promises we made to the world’s people”. (Source:
Keynote address by Dr Tedros Adhanom Ghebreyesus, WHO Director-General, to
the Regional Committee for the Western Pacific,
In relation to universal health coverage, KEI welcomes the spirit of change
embodied in the Draft Concept Note, but finds it lacking in specificity and
avoidant of an explicit recognition of the crisis of high prices for
medical technologies, and of the threat that the policy incoherence
recognized in the the United Nations Secretary-General’s High-Level Panel
on Access to Medicines (HLP) places on the ability to actualize universal
The UNHLP was tasked to address the incoherence between policies to promote
innovation and to achieve universal access. The key to overcoming policy
incoherence is to reduce reliance upon and eventually abandon the practice
of using high prices and time limited patent monopolies as the incentive to
invest in R&D. Delinkage models expand the role of direct funding of
research and subsidies for trial costs, and use money, rather than
monopolies, as the incentive mechanism. In order to truly fulfill the right
to health, it is imperative that the progressive implementation of
delinkage becomes a core element of the WHO commitment to achieve universal
health coverage. Without delinkage of R&D costs from the prices of drugs,
vaccines and other health technologies, access will always be constrained
and unequal, an outcome inconsistent with the goals expressed above.
The WHO GPW should envision a pathway to evaluate and implement the
alternative business models that are consistent with universal access to
products, and that means, in practical terms, progressive implementation of
delinkage of R&D costs from the prices of products, something that is
essential to reduce prices without undermining innovation.
So long as governments rely upon the grant of a monopoly to induce
investments in R&D, there will be monopolies on new drugs and the high
prices that come with monopolies.
The first step in implementing delinkage is to undertake serious studies of
the feasibility of delinkage in specific cases, such as for specific
diseases or technologies, and/or in geographic areas and groups of
countries that consider the benefits of delinkage significant, as it
relates to their own national interests.
Such a study was proposed as an element in the recent WHA resolution on
cancer (WHA 70.12),but not included in the final version of the resolution.
The WHO has a variety of existing mandates that would authorize work on
delinkage, including feasibility studies of specific proposed approaches.
The Consultative Expert Working Group on Research and Development: Finance
and Development (CEWG), the Global Strategy and Plan of Action on Public
Health, Innovation, and Intellectual Property (GSPOA), and the cancer
resolution passed during the most recent World Health Assembly (WHA 70.12)
all provide enabling mandates, for example.
The WHO would not be alone in considering the feasibility of delinkage.
Several European governments and Members of the European Parliament have
supported work within the European Union on this topic, and there are
currently 16 U.S. Senators and 18 members of the U.S. House of
Representatives calling for a feasibility study or studies by the U.S.
National Academies (115th Congress, S.771 and HR 1776, Section 301.j).
Several developing countries have have proposed the creation of large
innovation inducement prize funds that would allow countries to take
measures to lower drug prices without having an adverse impact on R&D,
including several made to the WHO by developing countries during the CEWG
Delinkage was one of the options highlighted in the 2017 WHO Fair Pricing
Forum in the Netherlands, a key recommendation of the 2017 Lancet
Commission report, “Essential medicines for universal health coverage”, and
in a number of proposals by other experts from diverse backgrounds and by
key stakeholders in public health.
Delinkage is also an important component of proposals to induce the
development of, and facilitate access to, new drugs to address
antimicrobial resistance (AMR), including for example, a 2017 report
endorsed by the U.S. Presidential Advisory Council on Combating
Antibiotic-Resistant Bacteria (PACCARB), a September 2016 high level
meeting of the United Nations General Assembly on antimicrobial resistance,
and an earlier 2015 report by Chatham House.
We appreciate that the Draft Concept Note acknowledges the important role
that the WHO must play in coordinating collective action, and second the
comments of India at the 70th SEARO regional committee meeting in calling
for the WHO to lead negotiations on a global R&D agreement, which could
provide global norms for funding R&D as a public good (Source: SEARO RC70:
India calls on WHO to take the lead in negotiations of the R&D treaty
(General Programme of Work debate), https://www.keionline.org/node/2869).
This can be an important element of a broader strategy to implement the
progressive delinkage of R&D costs from product prices, and also to address
the need for enhancing R&D in areas of priority and creating more
transparency of R&D resource flows and outcomes.
In relation to the WHO Model List of Essential Medicines, we have the
following comments. Traditionally, the World Health Organization (WHO) has
defined essential medicines as those that “satisfy the health care needs of
the population...and are intended to be available within the context of
functioning health systems at all times...and at a price the individual and
the community can afford.” (Source: The Selection and Use of Essential
Medicines - WHO Technical Report Series, No. 914,
The WHO Expert Committee has been asked, several times, to create a
category in the EML for products that would be essential, if available at
If drugs are medically effective, but expensive, they should be placed in
an EML category for drugs that are medically essential but face challenges
regarding affordability. Governments and patients would take this as a
signal to implement policies to make these medically effective drugs
KEI is completing a review of 56 new anti-cancer drugs approved by the US
FDA from 2010 to 2016. 45 of the new drugs received a priority review
status by the US FDA. None of the 56 new drugs are on the WHO EML.
In a different analysis, KEI looked at the 28 drugs with unique active
ingredients the US National Cancer Institute (NCI) identified as approved
by the FDA to treat breast cancer. Of the 28, 18 were registered from 1953
to 1998, and of these, 12 are included in the current 2015 version of the
WHO EML. Ten were registered from 1999 to 2016, and of these, none are
included in the WHO EML.
A system of medical guidance that is consistently ignoring or excluding new
drugs for cancer needs to be reformed, and new options for dealing with
affordability and access are needed if we are serious about achieving
equality of health outcomes.
We welcome the Expert Committee’s decision to create a working group to
address the complex and rapidly evolving challenges posed by cancer. This
standing group could help identify treatable tumours of public health
relevance and prioritize and identify the medicines used to treat these
tumours, and also begin to evaluate and contribute to proposals to delink
R&D incentives from drug prices, as this is the fundamental policy change
that is needed.
New medicines are expensive due to policies, not physics, chemistry or
biology. A policy to grant an IPR monopoly, through patents, data
exclusivity or other IPR mechanisms, is designed solely to induce
investments in R&D. Countries can regulate or eliminate monopolies, and
some do. Malaysia recently regulated the patent monopoly on hepatitis C
medicines under a government use order, because of excessive pricing.
As countries wrestle with affordability issues, they can seek technical
assistance from the WHO or other entities in order to use lawful pathways
to ensure treatments are affordable and widely available — including
through the granting of compulsory licenses.
The WHO should, as you have suggested, be much more active in this regard;
rather than waiting passively for countries to approach the WHO for
assistance, the WHO could organize a series of regional workshops to share
expertise on various technical and practical aspects of compulsory
licenses, and other related topics including the ability of Members to
implement limitations on remedies for patent infringement, as is done in
the United States in the context of cases where courts may and often do
deny permanent injunctions even involving medical technologies, but order a
reasonable royalty to compensate for the non-voluntary use of the patented
CONFLICTS OF INTEREST - FENSA
We note that the Lancet Editorial reported that you will appoint a
“transformation czar and hire McKinsey consultants to manage the change.”
(Source: WHO launches new leadership, new priorities,
In terms of the selection of McKinsey to manage the Organization’s change,
what was the process employed by the WHO? Was it FENSA compliant? Did WHO
require McKinsey to declare any conflicts of interest? How much will
McKinsey receive for its services in relation to change management? Who is
paying for the McKinsey work?
KEI is concerned that McKinsey has other clients, most notably research
based drug and vaccine manufacturers, the Bill and Melinda Gates Foundation
and Microsoft, which create conflicts, as regards certain policies relating
to intellectual property rights and drug pricing. For this reason, the
relationship with McKinsey needs to be more transparent, and the WHO needs
to consider avoiding working with a firm that is not truly responsive to
the needs of the WHO, as it also is serving others who have their own
interests and values in the global health space.
In relation to WHO’s work on prequalification, we welcome the launch of a
pilot project for prequalifying two biosimilar medicines - 1) rituximab and
2) trastuzumab. We underscore the important normative role that WHO’s
prequalification program (PQP) plays in providing quality assured standards
for a suite of health technologies. In order to safeguard the independence
of the PQP, WHO should consider funding this work from its core budget, and
not make the pre-qualification work excessively subject to the capricious
nature of voluntary funding.
In relation to expanding WHO’s work on transparency, we call on Member
states to provide the WHO with the mandate to explore norms and mechanisms
to enhance the transparency of R&D costs, prices and revenues.
While we acknowledge the importance of public and private sector funding of
research and development of pharmaceuticals, vaccines and other health
technologies, there is a paucity of data on investment flows and the costs
for research and development for specific products.
Of particular interest is data regarding the investments in each clinical
trial used to justify the registration of novel drugs, and to approve new
indications of older drugs.
We also note the importance of enhancing the public’s access to scientific
and medical data from clinical trials, including trials that fail. Access
to such data is critical to support advances in science, to enable the
appropriate scrutiny of trial design, and to evaluate and improve the
accuracy of reporting of such results. This has direct and negative
consequences for our knowledge about the safety and efficacy of medicines
prescribed to patients.
Policies that influence the pricing of health technologies or the
appropriate rewards for successful research outcomes can be better
evaluated when there is reliable, transparent and sufficiently detailed
data on the costs of R&D inputs (including information on the role of
public funding and subsidies), the medical benefits, and added therapeutic
value of products. The actual access or lack of access to products by
patients is highly dependent on affordable prices. In conclusion, access to
medicines is the bedrock of universal health coverage.
Knowledge Ecology International (KEI)
1621 Connecticut Avenue NW
Washington, DC 20009
Tel.: (202)332-2670 ext. 11
More information about the Ip-health